|
Published by: Business Monitor International
Published: Jan. 1, 2007 - 71 Pages
Table of Contents
- Chapter 1 - Executive Summary
- Egypt Pharmaceuticals & Healthcare Industry SWOT
- Egypt Economic SWOT
- Egypt Business Environment SWOT
- Chapter 2 - Egypt: Business Environment Ranking
- Table: Business Environment Ranking: Middle East & Africa
- Chapter 3 - Market Summary
- Chapter 4 - Regulatory Regime
- Intellectual Property Developments
- Pricing & Reimbursement Issues
- Chapter 5 - Industry Developments
- Healthcare Sector
- Avian Flu
- Foreign Manufacturing Sector
- Domestic Sector
- OTC Healthcare
- Research & Development Activity
- Chapter 6 - Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Table: Egypt Pharmaceuticals Market Trends
- Key Growth Factors - Macroeconomic
- Table: Egypt: Macroeconomic Data And Forecasts
- Prescription Market Forecast
- Table: Prescription Market Data
- OTC Market Forecast
- Table: OTC Market Data
- Generics Market Forecast
- Table: Generic Market Data
- Export/Import Market Forecast
- Table: Export/Import Market Data
- Other Healthcare Data & Forecasts
- Table: Other Healthcare Data
- Chapter 7 - Country Snapshot: Egypt Demographic Data
- Section 1: Population:
- Table: Demographic Indicators (2005)
- Table: Rural/Urban Breakdown
- Section 2: Education & Healthcare
- Table: Education
- Table: Healthcare: Vital Statistics
- Table: Healthcare: Expenditure
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators
- Table: Consumption and Stratification
- Table: Wages per year
- Chapter 8 - Competitive Landscape
- Company Monitor
- Profiles
- GlaxoSmithKline
- Novartis
- Egyptian International Pharmaceutical Industries Co (EIPICO)
- Bristol-Myers Squibb
- Pfizer
- Chapter 9 - BMI Forecast Modelling
- How we generate our industry forecasts
- Pharmaceutical Industry
- Sources
- Chapter 10 - Appendix: Regional Demographic Data
- The Long View: Data Over The Economic Cycle (2000-2007)
- Population
- Household Spending Per Capita, US$
- Private Consumption Per Capita, US$ PPP
- Market Size, GDP, US$bn
AbstractThe pharmaceutical market in Egypt was valued at about US$1.14bn in 2005, with healthcare and pharmaceutical expenditure accounting for 3.7% and 1.5% of GDP, respectively. However, as BMI cautions in its recently released Egypt Pharmaceuticals & Healthcare Report, stringent government pricing controls that fail to compensate for inflation will restrict future market growth. This is especially damaging, as the country is reliant on imports of raw materials. Currency fluctuations in the past have resulted in steep cost increases, although the Egyptian pound has been more stable of late against the US dollar.
About 7,600 drugs are manufactured locally, which accounts for about 93% of the domestic consumption. Egypt is the largest producer of pharmaceutical products in the region, with output estimated at some US$900mn. Research-based drugmakers account for approximately 65% of the total drug output in the country, of which 30% is through direct production, while sub-licensing to local companies accounts for 35%.
The drug registration system in Egypt has traditionally been convoluted and bureaucratic, although this is set to become a thing of the past with the authorities seeking to streamline the process. Currently, foreign drugmakers can wait up to three years to gain marketing approval for a drug. By speeding up the registration system, it is hoped that legitimate drugs will gain a greater share of the market, with the trade in fake and sub-standard products subsequently falling.
BMI's adjusted Business Environment Rankings for the Middle East reveal that Egypt is in 10th place ahead only of Lebanon Iran, Nigeria. This is primarily due to forecasts of sluggish market growth, coupled with the country's poor intellectual property regime. Egypt's large domestic manufacturing industry also acts as a barrier for investment, although the sheer size of the market, in regional terms, does offer some incentive.
Key Benefits of Report
Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.
Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments
Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.
Get Full Details About This Report >>
|
